KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Return on Sales for 10 consecutive years, with 188.84% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 18663.0% to 188.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 174.96% through Dec 2025, down 16403.0% year-over-year, with the annual reading at 174.96% for FY2025, 16403.0% down from the prior year.
  • Return on Sales hit 188.84% in Q4 2025 for CRISPR Therapeutics AG, down from 119.71% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.84% in Q2 2021 to a low of 18817.67% in Q4 2022.
  • Historically, Return on Sales has averaged 1188.42% across 5 years, with a median of 155.77% in 2021.
  • Biggest five-year swings in Return on Sales: crashed -1877778bps in 2022 and later skyrocketed 1881811bps in 2023.
  • Year by year, Return on Sales stood at 39.89% in 2021, then tumbled by -47079bps to 18817.67% in 2022, then surged by 100bps to 0.44% in 2023, then plummeted by -598bps to 2.21% in 2024, then crashed by -8429bps to 188.84% in 2025.
  • Business Quant data shows Return on Sales for CRSP at 188.84% in Q4 2025, 119.71% in Q3 2025, and 233.8% in Q2 2025.